• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Negative Efficacy of Desvenlafaxine and Fluoxetine for Children and Adolescents With MDD

Negative Efficacy of Desvenlafaxine and Fluoxetine for Children and Adolescents With MDD

March 1, 2018
Candace Good, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Candace Good, MD. Dr. Good has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Weihs et al, J Child Adolesc Psychopharmacol 2018;28(1):36–46

The debate about whether antidepressants work in children has been with us since the tricyclic era. A recent study evaluated the short-term efficacy and safety of a newer agent, desvenlafaxine (Pristiq).

This multi-center, randomized, double-blind, placebo-controlled study included 339 children and adolescents ages 7–17 who met DSM-IV-TR criteria for MDD. A fluoxetine 20 mg/day group was included as a reference for assay sensitivity, but not as a comparison to the study drug. Enrolled patients had a Children’s Depression Rating Scale—Revised (CDRS-R) total score > 40 at baseline. Patients were excluded from the study if they had psychotic features, if they had a personal or family history of bipolar disorder or suicide, or if they were felt to be at significant risk of suicide.

Patients were randomly assigned (1:1:1) to placebo, desvenlafaxine, or fluoxetine. Desvenlafaxine dose was chosen by body weight: 20 to < 35 kg: 25 mg/day; 35 to < 70 kg: 35 mg/day; and ≥ 70 kg: 50 mg/day. The patients were assessed weekly for the first month and again at weeks 6 and 8. The primary endpoint, change in the CDRS-R score from baseline to week 8, did not differ statistically from placebo (-23.1) for either desvenlafaxine (-22.6) or fluoxetine (-24.8). Adverse events (AE) attributed to medications were present in all study groups (desvenlafaxine, 28.7%; fluoxetine, 32.1%; and placebo, 34.8%). The most common treatment-emergent AEs were headache, upper abdominal pain, and nausea. There were no deaths in the study, but 5 patients receiving either desvenlafaxine or fluoxetine experienced serious AEs—suicidal ideation, a suicide attempt, disinhibition, and postpartum hemorrhage.

CCPR’s take
High placebo response rates in the pediatric population make it difficult to demonstrate the benefit of even established treatments such as fluoxetine, and clinicians should closely monitor for suicidal thoughts during initial stages of treatment with SSRIs and SNRIs. New-onset suicidal ideation was reported for 8, 10, and 7 patients in the desvenlafaxine, fluoxetine, and placebo groups, respectively; suicidal behavior was reported for 1 fluoxetine-treated patient, who reported suicidal ideation at baseline.

But more importantly, this landmark publication of a negative study, where neither desvenlafaxine nor fluoxetine were efficacious for treating MDD in children and adolescents, was conducted with financial and medical writing support from Pfizer Inc. As we go to press, another negative study for depression in children is being published on desvenlafaxine by the same journal. There appears to be a sea change happening on the heels of the final rule from the FDA, which severely penalizes (through fines) the suppression of negative studies.
Child Psychiatry
KEYWORDS child_psychiatry research-update
Candace Good, MD.

Antidepressant-Induced Suicidality: What It Is and What You Should Do

More from this author
www.thecarlatreport.com
Issue Date: March 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test for Anxiety - Children and Adolescents, CCPR, March/April 2018
Negative Efficacy of Desvenlafaxine and Fluoxetine for Children and Adolescents With MDD
Note From the Editor-in-Chief
Benzodiazepines in Children and Adolescents
Differentiating ADHD From Anxiety: Tips for Clinicians
Acting Out: Is It Anxiety?
Azithromycin for Acute-Onset Obsessive-Compulsive Disorder in Children
Celecoxib as Adjunctive Treatment in Acute Mania
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • teen_depression.jpeg
    Child Psychiatry

    Assessment of Non-Suicidal Self-Injury in Children and Adolescents

    Learn how to assess and intervene with NSSI, including ideas for supporting autonomy while addressing the behavior.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.